Document is current
Any future updates will be listed below
-
Authors
Landgren, Ola https://orcid.org/0000-0001-6485-4839
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 25 November 2025
Revised: 2 March 2026
Accepted: 20 April 2026
First Online: 5 May 2026
Competing interests
: OL has received grant support from: U.S. National Cancer Institute (NCI)/National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), Paula and Rodger Riney Multiple Myeloma Research Program Fund, Tow Foundation, Myeloma Solutions Fund, Cannon Guzy Family Fund, Amgen, J&J, and Pfizer; has received honoraria for scientific talks/participated in advisory boards for: Adaptive, Amgen, Binding Site, BMS, J&J, Pfizer, Regeneron, and Sanofi; and served on Independent Data Monitoring Committees (IDMC) for international randomized trials by: Takeda, Merck, Janssen, Theradex, and Arcellx/Kite.
